Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 17;12(1):176.
doi: 10.1186/s13148-020-00967-6.

Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis

Antonella De Lillo  1 , Gita A Pathak  2   3 , Flavio De Angelis  1   2   3 , Marco Di Girolamo  4 , Marco Luigetti  5   6 , Mario Sabatelli  6   7 , Federico Perfetto  8 , Sabrina Frusconi  9 , Dario Manfellotto  4 , Maria Fuciarelli  1 , Renato Polimanti  10   11
Affiliations

Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis

Antonella De Lillo et al. Clin Epigenetics. .

Abstract

Hereditary transthyretin (TTR) amyloidosis (hATTR) is a rare life-threatening disorder caused by amyloidogenic coding mutations located in TTR gene. To understand the high phenotypic variability observed among carriers of TTR disease-causing mutations, we conducted an epigenome-wide association study (EWAS) assessing more than 700,000 methylation sites and testing epigenetic difference of TTR coding mutation carriers vs. non-carriers. We observed a significant methylation change at cg09097335 site located in Beta-secretase 2 (BACE2) gene (standardized regression coefficient = -0.60, p = 6.26 × 10-8). This gene is involved in a protein interaction network enriched for biological processes and molecular pathways related to amyloid-beta metabolism (Gene Ontology: 0050435, q = 0.007), amyloid fiber formation (Reactome HSA-977225, q = 0.008), and Alzheimer's disease (KEGG hsa05010, q = 2.2 × 10-4). Additionally, TTR and BACE2 share APP (amyloid-beta precursor protein) as a validated protein interactor. Within TTR gene region, we observed that Val30Met disrupts a methylation site, cg13139646, causing a drastic hypomethylation in carriers of this amyloidogenic mutation (standardized regression coefficient = -2.18, p = 3.34 × 10-11). Cg13139646 showed co-methylation with cg19203115 (Pearson's r2 = 0.32), which showed significant epigenetic differences between symptomatic and asymptomatic carriers of amyloidogenic mutations (standardized regression coefficient = -0.56, p = 8.6 × 10-4). In conclusion, we provide novel insights related to the molecular mechanisms involved in the complex heterogeneity of hATTR, highlighting the role of epigenetic regulation in this rare disorder.

Keywords: Amyloidosis; Epigenetics; Methylation; Modifier gene; Val30Met mutation; hATTR.

PubMed Disclaimer

Conflict of interest statement

Drs. Fuciarelli and Polimanti received research grants from Pfizer Inc. to conduct epigenetic studies of hATTR. The other authors reported no biomedical financial interests or potential conflicts of interest.

Figures

Fig. 1
Fig. 1
Methylation levels (beta-values) of cg09097335 site in carriers (cases) vs. non-carriers (controls) of amyloidogenic mutations. Regression line is shown in blue. The M values of this comparison are reported in Additional file 1. Standardized regression coefficient and p value reported are derived from the analysis conducted on the M values
Fig. 2
Fig. 2
Upper Panel: Co-expression of TTR and BACE2 in liver and in hATTR target organs; Bottom Panel: Co-expression of TTR, DSG2, DSC2, DSC3, and B4GALT6 in hATTR target organs (transcriptomic data from GTEx project, available at https://www.gtexportal.org/)
Fig. 3
Fig. 3
BACE2 protein interaction network. Node color of the protein is proportional to the interaction score with BACE2. Connector shade and width are proportional to the interaction confidence, highest, high, and medium
See this image and copyright information in PMC

References

    1. Palaninathan SK. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr Med Chem. 2012;19(15):2324–2342. doi: 10.2174/092986712800269335. - DOI - PubMed
    1. Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19. doi: 10.1186/2047-9158-3-19. - DOI - PMC - PubMed
    1. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15(3):181–186. doi: 10.1080/13506120802193720. - DOI - PMC - PubMed
    1. Conceicao I. Clinical features of TTR-FAP in Portugal. Amyloid. 2012;19(Suppl 1):71–72. doi: 10.3109/13506129.2012.673184. - DOI - PubMed
    1. Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3–S13. doi: 10.1097/WCO.0000000000000288. - DOI - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts